1. Home
  2. FGBI vs MOLN Comparison

FGBI vs MOLN Comparison

Compare FGBI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Guaranty Bancshares Inc.

FGBI

First Guaranty Bancshares Inc.

HOLD

Current Price

$10.81

Market Cap

151.6M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$3.82

Market Cap

143.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGBI
MOLN
Founded
1934
2004
Country
United States
Switzerland
Employees
346
134
Industry
Savings Institutions
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
151.6M
143.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FGBI
MOLN
Price
$10.81
$3.82
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
22.5K
3.6K
Earning Date
04-27-2026
05-12-2026
Dividend Yield
0.44%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$567.70
N/A
Revenue Next Year
N/A
$374.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.31
$3.41
52 Week High
$11.02
$5.36

Technical Indicators

Market Signals
Indicator
FGBI
MOLN
Relative Strength Index (RSI) 63.31 45.21
Support Level $7.98 $3.61
Resistance Level N/A $3.96
Average True Range (ATR) 0.42 0.13
MACD 0.07 0.00
Stochastic Oscillator 75.66 33.33

Price Performance

Historical Comparison
FGBI
MOLN

About FGBI First Guaranty Bancshares Inc.

First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: